FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy

Gefitinib, an epidermal growth factor receptor–tyrosine kinase inhibitor (EGFR‐TKI), is an effective treatment for non‐small‐cell lung cancer (NSCLC) with EGFR activating mutations, but inevitably, the clinical efficacy is impeded by the emergence of acquired resistance. The tumor suppressor gene FB...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yi, Yin, Chunli, Wang, Yuli, Lv, Hanlin, Wang, Wenqing, Huang, Yurong, Perez‐Losada, Jesus, Snijders, Antoine M., Mao, Jian‐Hua, Zhang, Pengju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983212/
https://www.ncbi.nlm.nih.gov/pubmed/29633504
http://dx.doi.org/10.1002/1878-0261.12200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983212/
https://www.ncbi.nlm.nih.gov/pubmed/29633504
http://dx.doi.org/10.1002/1878-0261.12200

Ejemplares similares